Abstract
Abstract
Purpose
To provide first evidence of lymph node (LN) staging using CT scan and its prognostic value in variant histologies of bladder cancer. This knowledge may optimize patient management with variant histologies based on CT morphological findings.
Methods
Preoperative CT scans of patients with variant histologies who underwent RC between 2004 and 2019 were reanalyzed by two independent radiologists in a blinded review process. Specificity, sensitivity, and accuracy for LN staging as well as LN characteristics were evaluated. Correlation with survival was investigated by Kaplan–Meier method, log-rank test and multivariate analysis.
Results
1361 patients with primary tumor of the bladder underwent RC, of which 163 (12%) patients revealed variant histologies. 65 (47.8%) patients have shown an urothelial variant (UV) and 71 (52.2%) a non-urothelial variant (NUV). LN metastases were found in 18 (27.7%) patients with UV and 21 (29.6%) patients with NUV. The accuracy to detect LN metastasis for all variant histologies was 62% with a sensitivity of 46% and a specificity of 70%. Subgroups of UV and NUV revealed an accuracy of 67% and 57%. An increased number of regional LN (HR 2.8; 1.34–6.18) and the loss of fatty hilum (HR 0.36, 0.17–0.76) were prognostic parameters. In multivariate analysis, a fatty hilum (HR 0.313, 0.104–0.945) and the presence of lymph node metastases (HR 2.866, 1.140–7.207) were prognostic.
Conclusion
This first study on CT morphological behavior of variant histologies revealed an accuracy of UV and NUV comparable to UC with low specificity for all variant histologies. CT scan prior RC should be interpreted in regard to histological subtypes.
Funder
Horst-Lühl-Stiftung
Ludwig-Maximilians-Universität München
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30
2. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J et al (2019) European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update. Eur Urol 76:639–657
3. Witjes JA, Bruins M, Compérat E, Cowan NC, Gakis G, Hernández V et al (2018) EAU guidelines on muscle-invasive and metastatic bladder cancer 2018. European Association of Urology Guidelines 2018 Edition. European Association of Urology Guidelines Office, Arnhem
4. Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, Kikuchi E et al (2020) Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395:1547–1557
5. Moschini M, D’Andrea D, Korn S, Irmak Y, Soria F, Compérat E et al (2017) Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol 14:651–668
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献